HPLC–high-Resolution Mass Spectrometry with Polarity Switching for Increasing Throughput of Human in vitro Cocktail Drug–Drug Interaction Assay

References

• Zhang L , ZhangYD, ZhaoP, HuangSM. Predicting drug–drug interactions: an FDA perspective. AAPS J.11 (2), 300–306 (2009).
   PubMed Web of Science ®Google Scholar
• Feng WY . Mass spectrometry in drug discovery: a current review. Curr. Drug Discov. Technol.1 (4), 295–312 (2004).
   PubMedGoogle Scholar
• Lee MS . Integrated Strategies For Drug Discovery Using Mass Spectrometry. Wiley-Interscience, Hoboken, NJ, USA (2005).
   Google Scholar
• Kola I , LandisJ. Can the pharmaceutical industry reduce attrition rates?Nat. Rev. Drug Discov.3 (8), 711–715 (2004).
   PubMed Web of Science ®Google Scholar
• Varma MV , KimotoE, ScialisRet al. Transporter-mediated hepatic uptake plays an important role in the pharmacokinetics and drug-drug interactions of montelukast. Clin. Pharmacol. Ther.101 (3), 406–415 (2017).
   PubMed Web of Science ®Google Scholar
• Rodrigues AD , TaskarKS, KusuharaH, SugiyamaY. Endogenous probes for drug transporters: balancing vision with reality. Clin. Pharmacol. Ther.103 (3), 434–448 (2017).
   PubMed Web of Science ®Google Scholar
• Lin JH . Sense and nonsense in the prediction of drug–drug interactions. Curr. Drug Metab.1 (4), 305–331 (2000).
   PubMed Web of Science ®Google Scholar
• US FDA . In Vitro Metabolism- and Transporter- Mediated Drug-Drug Interaction Studies. Guidance for Industry. Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CV) (2017). www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM581965.pdf.
   Google Scholar
• Huang SM , StrongJM, ZhangLet al. New era in drug interaction evaluation: US Food and drug administration update on CYP enzymes, transporters, and the guidance process. J. Clin. Pharmacol.48 (6), 662–670 (2008).
   PubMed Web of Science ®Google Scholar
• Huang SM , ZhaoH, LeeJIet al. Therapeutic protein–drug interactions and implications for drug development. Clin. Pharmacol. Ther.87 (4), 497–503 (2010).
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T , ChuX, GibsonCet al. Drug–drug interaction studies: regulatory guidance and an industry perspective. AAPS J.15 (3), 629–645 (2013).
   PubMed Web of Science ®Google Scholar
• US FDA . Guidance for Industry, Drug Interaction Studies – Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations (2012). www.fda.gov/downloads/drugs/guidances/ucm292362.pdf.
   Google Scholar
• Zhang L , ReynoldsKS, ZhaoP, HuangSM. Drug interactions evaluation: an integrated part of risk assessment of therapeutics. Toxicol. Appl. Pharmacol.243 (2), 134–145 (2010).
   PubMed Web of Science ®Google Scholar
• Huang SM , TempleR, ThrockmortonDC, LeskoLJ. Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin. Pharmacol. Ther.81 (2), 298–304 (2007).
   PubMed Web of Science ®Google Scholar
• Ramanathan R , ReydermanL, KulmatyckiKet al. Disposition of loratadine in healthy volunteers. Xenobiotica37 (7), 753–769 (2007).
   PubMed Web of Science ®Google Scholar
• Liu M , SuX, LiG, ZhaoG, ZhaoL. Validated UPLC–MS/MS method for simultaneous determination of simvastatin, simvastatin hydroxy acid and berberine in rat plasma: application to the drug–drug pharmacokinetic interaction study of simvastatin combined with berberine after oral administration in rats. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.1006, 8–15 (2015).
   PubMed Web of Science ®Google Scholar
• Ciofi L , AncillottiC, ChiuminattoUet al. Liquid chromatographic–tandem mass spectrometric method for the simultaneous determination of alkylphenols polyethoxylates, alkylphenoxy carboxylates and alkylphenols in wastewater and surface-water. J. Chromatogr. A1362, 75–88 (2014).
   PubMed Web of Science ®Google Scholar
• Sreenivasulu V , RameshM, KumarIJ, BabuRV, PilliNR, KrishnaiahA. Simultaneous determination of carisoprodol and aspirin in human plasma using liquid chromatography–tandem mass spectrometry in polarity switch mode: application to a human pharmacokinetic study. Biomed. Chromatogr.27 (2), 179–185 (2013).
   PubMed Web of Science ®Google Scholar
• Grau M , PaulyS, AliJet al. RBC-NOS-dependent S-nitrosylation of cytoskeletal proteins improves RBC deformability. PLoS ONE8 (2), e56759 (2013).
   PubMed Web of Science ®Google Scholar
• Bergeron M , BergeronA, Van AmsterdamP, FurtadoM, GarofoloF. Use of polarity switching for the simultaneous bioanalysis of analytes with three orders of magnitude difference in concentration by LC–MS/MS. Bioanalysis5 (15), 1911–1918 (2013).
   PubMed Web of Science ®Google Scholar
• Gajula R , PilliNR, RaviVBet al. Simultaneous determination of atorvastatin and aspirin in human plasma by LC–MS/MS: its pharmacokinetic application. Sci. Pharm.80 (4), 923–940 (2012).
   PubMedGoogle Scholar
• Shen D , PanMH, WuQLet al. LC–MS method for the simultaneous quantitation of the anti-inflammatory constituents in oregano (Origanum species). J. Agric. Food Chem.58 (12), 7119–7125 (2010).
   PubMed Web of Science ®Google Scholar
• Yan Z , CaldwellGW, MaherN. Unbiased high-throughput screening of reactive metabolites on the linear ion trap mass spectrometer using polarity switch and mass tag triggered data-dependent acquisition. Anal. Chem.80 (16), 6410–6422 (2008).
   PubMed Web of Science ®Google Scholar
• Apostolou C , KousoulosC, DotsikasYet al. An improved and fully validated LC–MS/MS method for the simultaneous quantification of simvastatin and simvastatin acid in human plasma. J. Pharm. Biomed. Anal.46 (4), 771–779 (2008).
   PubMed Web of Science ®Google Scholar
• Kluger B , BueschlC, NeumannNet al. Untargeted profiling of tracer-derived metabolites using stable isotopic labeling and fast polarity-switching LC-ESI-HRMS. Anal. Chem.86 (23), 11533–11537 (2014).
   PubMed Web of Science ®Google Scholar
• Kwok WH , ChoiTLS, TsoiYYK, LeungGNW, WanTSM. Screening of over 100 drugs in horse urine using automated on-line solid-phase extraction coupled to liquid chromatography–high resolution mass spectrometry for doping control. J. Chromatogr. A1490, 89–101 (2017).
   PubMed Web of Science ®Google Scholar
• Zientek M , MillerH, SmithDet al. Development of an in vitro drug–drug interaction assay to simultaneously monitor five cytochrome P450 isoforms and performance assessment using drug library compounds. J. Pharmacol. Toxicol. Methods58 (3), 206–214 (2008).
   PubMedGoogle Scholar
• Zientek M , YoudimK. Simultaneous determination of multiple CYP inhibition constants using a cocktail-probe approach. Methods Mol. Biol.987, 11–23 (2013).
   PubMedGoogle Scholar
• Huguet J , GaudetteF, MichaudV, TurgeonJ. Development and validation of probe drug cocktails for the characterization of CYP450-mediated metabolism by human heart microsomes. Xenobiotica doi:10.1080/00498254.2018.1438684 (2018) ( Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Barecki ME , CascianoCN, JohnsonWW, ClementRP. In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes. Drug Metab. Dispos.29 (9), 1173–1175 (2001).
   PubMed Web of Science ®Google Scholar
• Ghosal A , GuptaS, RamanathanRet al. Metabolism of loratadine and further characterization of its in vitro metabolites. Drug Metab. Lett.3 (3), 162–170 (2009).
   PubMedGoogle Scholar
• Kosoglou T , SalfiM, LimJM, BatraVK, CayenMN, AffrimeMB. Evaluation of the pharmacokinetics and electrocardiographic pharmacodynamics of loratadine with concomitant administration of ketoconazole or cimetidine. Br. J. Clin. Pharmacol.50 (6), 581–589 (2000).
   PubMed Web of Science ®Google Scholar